European Association for the Study of Diabetes Annual Meeting, 1999: treatment modalities

Bloomgarden, Zachary T.; Bloomgarden, Z T
July 2000
Diabetes Care;Jul2000, Vol. 23 Issue 7, p1012
Academic Journal
Highlights the results of the 35th Annual Meeting of the European Association for the Study of Diabetes held in Brussels, Belgium in September 1999. Effectiveness of oral agents in treating hyperglycemia; Mechanism of action of thiazolidinediones; Variability of insulin absorption.


Related Articles

  • Insulin Glargine (rDNA origin) Injection.  // AHFS Consumer Medication Information;Sep2020, p1 

    Insulin glargine is used to treat type 1 diabetes (condition in which the body does not produce insulin and therefore cannot control the amount of sugar in the blood). It is also used to treat people with type 2 diabetes (condition in which the body does not use insulin normally and, therefore,...

  • Glycemic Variability in Patients with Type 2 Diabetes on Basal Insulin and Fixed Combination Oral Antidiabetic Treatment - Results of a Pilot Study. De Mattia, Giancarlo; Laurenti, Oriana; Moretti, Arianna; Mollica, Maria R. // Diabetes;Jun2007 Supplement 1, Vol. 56, pA148 

    Type 2 diabetes (T2DM) is a progressive disease, which may eventually require insulin therapy when glycemic control fails using oral antidiabetic drugs (OADs) alone. Once-daily glargine ensures a 24-hr basal insulin replacement in T2DM patients, which can allow lower glycemic fluctuations during...

  • Pharmacotherapy-Based Problems in the Management of Diabetes Mellitus: Needs Much More to be Done! Ali, N.; Shah, S. W. A.; Khan, J.; Rehman, S.; Imran, M.; Hussian, I.; Shehbaz, N.; Jamshed, H.; Khan, S. // Journal of Young Pharmacists;2010, Vol. 2 Issue 3, p311 

    A total of 856 diabetic patients were evaluated for pharmacotherapy-based problems like for possible drug interactions, adverse drug reactions, and other mismatches, if any. Poor correlation between the advised insulin therapy and patients' fasting blood glucose levels (12%, n=103) was observed....

  • No Need for the Needle (at First). Davidson, Mayer B. // Diabetes Care;Oct2008, Vol. 31 Issue 10, p2070 

    The author comments on a study by Chen et al. which describes an approach to the initial treatment of newly diagnosed type 2 diabetic patients with severe hyperglycemia entailing intensive insulin therapy during 10 to 14 days of hospitalization. According to the author, one should carefully...

  • Troglitazone for insulin-resistant diabetes.  // American Family Physician;4/1/1997, Vol. 55 Issue 5, p1985 

    Presents information about the approval of the Food and Drug Administration on troglitazone (Rezulin) as the first anti-diabetes drug that targets the underlying cause of type II diabetes mellitus. Required dosage of troglitazone for patients receiving insulin injection; Most common adverse...

  • Fracture risk in patients with type 2 diabetes under different antidiabetic treatment regimens: a retrospective database analysis in primary care. Pscherer, S.; Kostev, K.; Dippel, F. W.; Rathmann, W. // Diabetes, Metabolic Syndrome & Obesity: Targets & Therapy;Feb2016, Vol. 9, p17 

    Aim: Type 2 diabetes is associated with an increased risk of fractures. There are a few studies on the effects of diabetes treatment on fracture risk. The aim was to investigate the fracture risk related to various types of insulin therapy in primary care practices. Methods: Data from 105,960...

  • INITIATING INSULIN. Lasserson, Daniel // Pulse;11/16/2006, Vol. 66 Issue 43, p54 

    The article focuses on reducing vascular risk in diabetes patients on insulin in Great Britain. In a research of the United Kingdom Prospective Diabetes Study, it revealed that using glucose control of blood pressure resulted to 25% reduction in microwave events. The initial strategies used by...

  • BACK ON TRACK. HOPE, TONI GERBER // Better Homes & Gardens;Nov2015, Vol. 93 Issue 11, p163 

    The article focuses on the threat of diabetes and offers suggestions for reducing diabetes, which includes focusing of blood sugar levels and weight loss.

  • Inhaled insulin effective long-term.  // Pulse;6/7/2004, Vol. 64 Issue 23, p9 

    Reports on research from the U.S. on the efficacy of inhaled insulin on glycaemic control and pulmonary function in patients with diabetes.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics